Myonexus Therapeutics: 0 to >$200 Million in Less than Three Years
Myonexus Therapeutics: 0 to >$200 Million in Less than Three Years
Dr. Triplett will share the story of how Myonexus Therapeutics was formed and quickly achieved a $200+ million exit in less than three years. Attendees will learn about Columbus' life sciences innovation strengths and how the Columbus Region can build upon Myonexus and other successes to create a sustainable, larger life sciences venture and innovation ecosystem. Dr. Michael Triplett is a co-founder and Managing Member of 1787 Bio, LLC, a life sciences investment organization based
Read More